Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenABCWY+OMV vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The MenABCWY+OMV vaccine is an investigational pentavalent (5-in-1) meningococcal conjugate and protein-based vaccine designed to protect against invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. It combines the antigenic components of existing quadrivalent conjugate vaccines (MenACWY) with recombinant proteins from serogroup B and outer membrane vesicle (OMV) from the New Zealand strain NZ98/254. The mechanism of action involves inducing protective antibodies against the polysaccharide capsules of serogroups A, C, W, Y as well as surface proteins specific to serogroup B. The addition of OMV enhances immunogenicity for group B strains. This combination aims to simplify vaccination schedules by providing broad protection in a single product for adolescents and young adults at risk for invasive meningococcal disease[5][6][7][8]. The developer is GSK.
- Brand names
- Penmenvy
- Other names
- pentavalent meningococcal vaccine5-in-1 meningococcal vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis PorA P1.4 / outer membrane vesicle surface antigensfHbp (Factor H-binding protein)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideNadA (Neisserial adhesin A)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NHBA (Neisserial heparin-binding antigen)
Beyond the preview
Go deeper on MenABCWY+OMV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenABCWY+OMV vaccine.